載入中
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
前收盤價
US$1.87
+US$0.01 · +0.54%
盤中時間採用ET。市場資料可能有所延遲。
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
日內區間
目前US$1.87
52週區間
目前US$1.87
盤中時間採用ET。市場資料可能有所延遲。
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
日內區間
目前US$1.87
52週區間
目前US$1.87
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 3267.2萬 USD | 1270.9萬 USD | 322.9萬 USD | 537.74萬 USD | 2514.74萬 USD |
| 銷售、一般及管理費用 | 2371.3萬 USD | 678.5萬 USD | 500.5萬 USD | 567.52萬 USD | 758.08萬 USD |
| 營業費用 | 5638.5萬 USD | 1949.4萬 USD | 823.4萬 USD | 1105.26萬 USD | 3272.82萬 USD |
| 利息收入 | 381.9萬 USD | 191.4萬 USD | — | — | — |
| 利息支出 | — | 2.3萬 USD | 2.4萬 USD | 4443 USD | 949 USD |
| 折舊和攤銷 | — | — | 8000 USD | 11.33萬 USD | 10.9萬 USD |
| 營業利益 | −5638.5萬 USD | −1949.4萬 USD | −823.4萬 USD | −1105.26萬 USD | −3272.82萬 USD |
| 淨利 | −5259.9萬 USD | −1760.2萬 USD | −771.1萬 USD | −1104.79萬 USD | −3247.44萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.40
上漲空間 135.29%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM174.63萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI156.82萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF51.47萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO26.53萬0.00%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC21.25萬0.02%13.17億 USD0.60%US$183+0.11%
Fidelity Enhanced Small Cap ETFFESM11.5萬—64.1億 USD0.28%US$45.46+0.46%
ALPS Medical Breakthroughs ETFSBIO8.82萬0.05%1.91億 USD0.50%US$55.04+2.03%
Dimensional - US Core Equity 2 ETFDFAC6.11萬0.00%885.96億 USD0.21%US$45.33+0.49%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMALPS Medical Breakthroughs ETFSBIODimensional - US Core Equity 2 ETFDFACAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
